Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient

RAFAEL APORTA RODRÍGUEZ, JUAN LUIS ESCOBAR VEDIA, ANTONIO MIGUEL NAVARRO CASTRO, GUADALUPE AGUILAR GARCÍA, ANTONIO CABRERA TORRES
Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain

We present the case of a woman with Gaucher disease who was being given alglucerase as enzyme replacement therapy. She was found to be pregnant: the treatment was continued. She gave birth to a healthy son after a spontaneous vaginal delivery at term.

Type I Gaucher’s disease (GD) is an inherited metabolic disorder resulting from the deficient activity of β-glucocerebrosidase and the subsequent accumulation of the glycolipid glucosylcereamide in macrophages.

A 30-year-old female Type I GD patient, had received enzyme replacement therapy (ERT) for 13 months with alglucerase (Ceredase™, Genzyme Corp. Cambridge, MA, USA) at a dose of 30 IU/kg every two weeks, when she was found to be 15 weeks pregnant during a routine ultrasound to monitor the size of her spleen. This patient was first seen at our hospital at the age of 24 with extreme pallor, cachexia, hepatosplenomegaly and a history of anemia and thrombocytopenia. In the following years she developed some typical GD symptoms such as bleeding, anemia, massive hepatosplenomegaly and slight skeletal Erlenmeyer flask deformity.

Treatment with alglucerase was started on February 18th, 1994. In May the patient experienced an episode of severe uterine bleeding, with hemoglobin dropping (8.6 g/dL) even below baseline values, after an initial adequate hematologic response (hemoglobin from 8.6 to 10.5 g/dL and platelets from 48,000 to 56,000/mm³) (Figure 1). An ultrasound showed a right sided cystic tumor and signs of endometriosis. To control the hormonal dysfunction, Gynacrin-therapy (Leuproveline; Gn-RH/LH-RH) was started while maintaining ERT. As expected, the patient became amenorrheic, and no further bleeding episodes occurred. In the following months her clinical condition improved again. On April 7, 1995 the pregnancy was already over and uterine ultrasound showed no fetal abnormalities, it was decided to continue ERT. As, by then, the first trimester of pregnancy was already over and uterine ultrasound showed no fetal abnormalities, it was decided to continue ERT. In the 40th week of pregnancy spontaneous contractions started, resulting in a successful vaginal delivery of a 3.5 kg boy, with no abnormalities (Apgar test: 9 at 1 and 10 min). Uterine bleeding was in the low-normal range and the placenta was judged normal. Given the satisfactory clinical course it was decided to maintain ERT and allow maternal breast-feeding. The baby continues to have a steady and healthy development. The patient recovered well and continued to respond to ERT (Figure 1).

ERT has shown to be safe and effective in the treatment of Type I GD.1 So far, no complete clinical descriptions of pregnant GD patients treated with alglucerase throughout pregnancy have been published. There is only one abstract briefly describing 10 patients receiving alglucerase during any part of pregnancy,2 revealing two adverse outcomes, and only one full term delivery while on ERT for the whole pregnancy. Obstetric aspects of GD patients not receiving ERT have already been described.3-5 These reports show that GD patients are at risk of complications during pregnancy. Therefore, it might be suggested that alglucerase could contribute to increase the patient’s health status during pregnancy, and delivery. As no reproductive studies have been performed on the use of alglucerase, the decision to treat GD patients during pregnancy should be made on an individual basis by the patients physician, considering the disease status of the patient and possible risks.

Key words
Gaucher disease, pregnancy, alglucerase

Correspondence
Dr. Rafael Aporta Rodríguez, Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Avda de las Fuerzas Armadas s/n, 18014 Granada, Spain.

References
Long-term follow-up of non-Hodgkin’s lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype

GIUSEPPE MAROTTA, CATIA BIGAZZI, MONICA BOCCHIA, FRANCESCO FORCONI, FRANCESCO LAURIA

Division of Hematology “A. Sclavo” Hospital, University of Siena, Italy

Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphomas treated with ProMACE-CytaBOM regimen were evaluated. Twenty-four out of 54 (45%) patients achieved a complete remission and 13 of them are still in continuous remission with a median survival of 53.5 months. Interestingly, in 16 patients with intermediate grade histology we obtained an overall response rate of 100%.

Among third-generation chemotherapy regimens, ProMACE-CytaBOM is considered a very effective protocol in patients with aggressive non-Hodgkin lymphomas (NHL), producing about a 70% rate of complete remission (CR) as first reported by Fisher and confirmed by subsequent studies.1-4

In our study 54 patients with aggressive NHL, 25 of whom at diagnosis, received ProMACE-CytaBOM chemotherapy according to the scheme proposed by Fisher et al. and updated by Longo et al.2,5 The patients’ clinical and histological characteristics are summarized in Table 1. All responding patients received a minimum of six cycles and almost all patients received 100% of the planned dose. Overall, 24 out of 54 (44.5%) patients achieved complete response (CR) and 20 (37%) a partial response (PR), reaching an overall response rate of 81%.

As expected, patients at diagnosis or with a more favorable histology and with a normal LDH serum level achieved better results, while differences in response rates were not observed when patients were analyzed according to age, sex, stage of disease, and mean dose intensity calculated for each single drug (Table 1). On the other hand, CR rates were significantly higher (p < 0.05) in previously untreated patients and in those with intermediate grade histology.

The estimated 5-year overall survival was 53%. When the analysis was done according to histological subtypes and previous therapy, untreated patients and those with intermediate histology showed statistically significant (p < 0.05) better survival curves (Figures 1 and 2).

Grade 3-4 neutropenia (WHO classification) recorded in 15 patients, and nausea and vomiting were the most important and frequent hematologic and non-hematologic side effects.

Our results, in agreement with previous reports,4,6-10 document an overall response rate of 81% with an apparent reduced number of CRs probably due to the higher median age of our patients, to a not negligible number of pre-treated cases and probably also to the very strict criteria adopted in defining CR. However, despite the reduced CR rate, 54% of complete responders in our study are still in CR after a considerable period. Interestingly, patients with intermediate grade of malignancy showed a response rate of 100% regardless of the previous therapy. The small number of this very lucky series of patients does not allow further analysis.

In conclusion our results, although less impressive in terms of CR rate than other previous reports1-6 document that 54% of complete responder patients are still in CR after a median of 53 months. Hematologic toxicity and side effects were acceptable and never

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CR</th>
<th>PR</th>
<th>CDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≤ 60 years</td>
<td>12/24 (50%)</td>
<td>8/24 (33%)</td>
<td>7/12 (58%)</td>
</tr>
<tr>
<td>&gt; 60 years</td>
<td>12/30 (40%)</td>
<td>12/30 (40%)</td>
<td>6/12 (50%)</td>
</tr>
<tr>
<td>Sex male</td>
<td>13/32 (40%)</td>
<td>13/32 (40%)</td>
<td>7/13 (54%)</td>
</tr>
<tr>
<td>female</td>
<td>11/22 (50%)</td>
<td>7/12 (32%)</td>
<td>6/11 (54%)</td>
</tr>
<tr>
<td>Stage I-II</td>
<td>9/18 (50%)</td>
<td>7/18 (39%)</td>
<td>6/9 (67%)</td>
</tr>
<tr>
<td>III-IV</td>
<td>15/36 (42%)</td>
<td>13/36 (36%)</td>
<td>7/15 (47%)</td>
</tr>
<tr>
<td>Histology intermediate grade</td>
<td>16/22 (73%)</td>
<td>6/22 (27%)</td>
<td>8/16 (50%)</td>
</tr>
<tr>
<td>high grade</td>
<td>8/32 (25%)</td>
<td>14/32 (44%)</td>
<td>5/8 (62%)</td>
</tr>
<tr>
<td>Therapy untreated 1 regimen</td>
<td>16/29 (55%)</td>
<td>9/29 (31%)</td>
<td>11/16 (69%)</td>
</tr>
<tr>
<td>&gt; 1 regimen</td>
<td>8/21 (40%)</td>
<td>9/21 (43%)</td>
<td>2/8 (25%)</td>
</tr>
<tr>
<td>LDH ≤ 450</td>
<td>16/29 (55%)</td>
<td>11/29 (38%)</td>
<td>8/16 (50%)</td>
</tr>
<tr>
<td>&gt; 450</td>
<td>8/25 (32%)</td>
<td>9/25 (36%)</td>
<td>5/8 (62%)</td>
</tr>
<tr>
<td>IPI low/low-intermediate intermediate-high/high</td>
<td>16/27 (59%)</td>
<td>10/27 (37%)</td>
<td>11/16 (69%)</td>
</tr>
<tr>
<td>Total</td>
<td>24/54 (44%)</td>
<td>20/54 (37%)</td>
<td>13/54 (24%)</td>
</tr>
</tbody>
</table>

Abbreviations: CR: complete response; PR: partial response; CCR: continuous CR.
lifethreatening, suggesting that the ProMACE-CytaBOM regimen is an effective and safe chemotherapeutic scheme.

**Key words**

Non Hodgkin lymphoma, ProMACE-CytaBOM regimen, long-term follow-up

**Correspondence**

Giuseppe Marotta, MD, Division of Hematology, “A. Sclavo” Hospital, via Tufi, 1, 53100 Siena, Italy. Phone: international +39-0577-586785 • Fax: international +39-0577-586185.

**Funding**

This work was supported in part by the Siena Section of the Associazione Italiana contro le leucemie (AIL).

**References**

Philadelphia positive acute lymphoblastic leukemia 16 years after the apparent cure of acute lymphoblastic leukemia. New leukemia or late relapse?

JOSEFA LUIS NAVARRO, JOSE DE BLAS ORLANDO, EDUARDO RÍOS HERRANZ, JOSÉ GONZÁLEZ CAMPOS, RICARDO PARODY, JUAN MANUEL RODRÍGUEZ FERNÁNDEZ

Department of Hematology and Hemotherapy, Virgen del Rocío University Hospital, Sevilla, Spain

A Philadelphia-positive ALL in an adult occurring 21 years after the initial diagnosis is reported here. This case raises the question as to whether or not this event is a relapse or a new leukemia. A possible role of interferon-α previously administered to the patient for a chronic viral hepatitis is discussed too.

Acute lymphoblastic leukemia (ALL) relapses occurring more than five years after achieving complete remission (CR) are unusual² and raise the possibility of a new neoplasm.²

We report a second leukemia 16 years after the cure of a childhood ALL. This second leukemia was Philadelphia chromosome (Ph1) positive, a poor prognostic factor. In addition, we discuss herein the possible role played by interferon-α (IF-α) in the etiopathogenesis of this new leukemia.

Case Report

A three-year-old child affected by ALL in 1974 received induction treatment, holocranial radiotherapy and intrathecal methotrexate and he achieved CR. Maintenance treatment was given until June 1977. After therapy for testicular relapse treatment was stopped in 1979.

In December 1990 a chronic viral C hepatitis was diagnosed and IF-α was given for three years, but was subsequently discontinued as it was ineffective.

In 1995, 21 years after the first diagnosis the patient presented with clinical and analytical signs of an apparent ALL relapse. Immunophenotyping revealed a B lineage common ALL. Reverse-transcription polymerase chain reaction (RT-PCR) with nested primers specific for minor breakpoint rearrangements (primers supplied by Oncogen RP, Cambridge, MA, USA) was positive giving rise to the expected bands in bcr/abl e1a2 rearrangements. No amplification was noted when transcripts from the patient were assayed with primers specific for major breakpoint rearrangements.

After receiving a single chemotherapy course, he died of septic abdominal infection.

In patients achieving long-lasting CR, late relapses are unusual and raise a controversial issue: relapse versus new leukemia.

Pagano et al.³ revealed that the actuarial estimated cumulative proportion of ALL patients with a secondary haematologic neoplasm at 5 and 10 years were 0.59% and 3.63%, respectively.

In our case, the lack of immunologic and molecular data from the first leukemia hampers understanding of whether we are facing a genuine relapse or a distinct ALL. The hypothesis of a different neoplasm is supported by two facts. Firstly, the strikingly long duration of our patient’s relapse-free survival (therefore, a drug-induced leukemia cannot fully discarded). Secondly, although in pediatric ALL, Ph1 can be absent at diagnosis, subsequently emerging as a consequence of clonal evolution,⁴ and a subset of good prognosis Ph1 ALL could exist,⁵ Ph1 is usually associated with aggressive disease, poor prognosis and no short term remissions.⁶

Nevertheless, a relapse cannot be completely ruled out. In this case IF-α, as an immune modulator, administered to the patient in previous years may have prompted the leukemia relapse.

IF-α can activate B-cells in malignant and non-malignant lymph nodes to proliferation and blast transformation.⁷ IF-α has been shown to regulate B-cell differentiation and to act as a natural regulator of B-cell functions. In some neoplasms of B-cell origin, especially myeloma, IF-α is able to stimulate the proliferation of Interkeukin-6 dependent cells of clonogenic tumor cells in vitro as well as in vivo.⁸

Key words

Acute lymphoblastic leukemia, late relapse, Philadelphia chromosome, interferon-α.

Correspondence

Josefa Luis Navarro, MD, Servicio de Hematología, Sa Planta Edf Laboratorios, Hospital Universitario Virgen del Rocío, Avda Manuel Suor t/s, 41013 Seville, Spain.

References

The bcr-abl rearrangement in T-lineage acute lymphoblastic leukemia

FRANCESCO FABBIANO, ALESSANDRA SANTORO, ROSARIA FELICE, PATRIZIA CATANIA, SONIA CANNELLA, IGNAZIO MAJOLINO

Divisione di Ematologia e Unità Trapianti di Midollo Osseo, Azienda Ospedaliero "V. Cenello", Palermo, Italy

The bcr-abl rearrangement in T-lineage ALL has been rarely described. In the last three years we studied all new patients with ALL at diagnosis by cytogenetic and molecular analysis. Three out of eleven T-lineage ALL patients presented the rearrangement and only one was Philadelphia positive.

The Philadelphia (Ph) chromosome, t(9;22) (q34;q11), is present in more than 95% of patients with chronic myelogenous leukemia (CML) and in 15-25% of adults with acute B-lineage lymphoblastic leukemia (ALL). In T-lineage ALL it has rarely been reported and singular cases of T-lineage adult ALL carrying the bcr-abl rearrangement have been recently described. A bcr-abl rearrangement in T-lineage ALL is thus a rare event and the clinical relevance of this translocation is currently unknown.

In the last three years we studied 25 new consecutive cases of ALL (14 B-lineage and 11 T-lineage). We present here the clinical, immunologic, cytogenetic and molecular features of three out of these T-lineage ALL patients presenting bcr-abl rearrangement at diagnosis.

Patient #1. A 15-year-old male was referred with a recent history of cough and fatigue. He was treated with daunomycin, vincristine, asparaginase, and prednisone and obtained a complete remission. He relapsed 7 months later, did not obtained a second remission and died 4 months later.

Patient #2. A 32-year-old male was admitted with acute leukemia. He was treated with idarubicin, cytarabine, vincristine and prednisone and obtained complete remission. He was later submitted to allogeneic peripheral blood transplantation from his HLA-identical sister while in first CR. The patient developed acute but not chronic GVHD. He relapsed 18 months later. He is actually in second CR after reinduction treatment.

Patient #3. A 47-year-old male was admitted with acute pericarditis. The chest X-ray and chest CT scan showed massive mediastinal enlargement and pleural and pericardial effusion. Blood counts were normal, but differential counts showed 20% blast cells. Bone marrow aspiration revealed 50% blast cells with cerebrocortical nuclear DNA. Pleural fluid contained 117.0 x 10^9/L blast cells. The patient was treated with daunoblastin, vincristine, asparaginase and prednisone and obtained complete remission. He was submitted to autologous peripheral staminal cell transplantation, but died of adult respiratory distress syndrome two weeks later.

Clinical and biological data are shown in Table 1. bcr-abl transcript was detected by RT-PCR and the rearrangements occur in all patients within the 5.8-kb M-bcr region associated with P210 bcr-abl expression; monoclonal rearrangement of the TCRg gene, but not of the IGH locus was also detected by PCR (Figure 1).

Ph+ CML is known to arise in a multipotent hematopoietic stem cell. This is also shown by the fact that Ph translocation and/or bcr-abl expression can be simultaneously found in cells of myeloid and lymphoid lineage. Occasional reports of Ph+ T-cell blast crisis of CML provide evidence that T-cell precursors can be involved in Ph+ leukemic transformation. Single cases of T-lineage ALL with Ph translocation or bcr-abl rearrangement have also been reported.

The characteristics of our three bcr-abl T-ALL cases are indistinguishable from other T-lineage ALL. Two presented with mediastinal enlargement and one patient had intermediate characteristics between T-ALL and T mediastinal lymphoblastic lymphoma. We do not know whether the presence of bcr-abl gene rearrangement makes the prognosis of T-lineage ALL worse, but two out of three patients had bad prognosis characteristics such as early T phenotype,
high WBC count and extranodal involvement. The presence of \textit{bcr-abl} rearrangement in T-ALL is a rare event. Our cases are probably an occasional series. Nevertheless the real incidence and the significance of \textit{bcr-abl} rearrangement in T-lineage ALL is not known. We think that further studies on the molecular biology of T-ALL could be useful.

\textbf{Funding}

This work is in part supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and by a grant from the Associazione Italiana contro le Leucemie (AIL).

\textbf{Correspondence}

Francesco Fabbiano, MD, Divisione di Ematologia, Azienda Ospedaliera "V. Cervello", via Trabucco 180, 90146 Palermo, Italy. Phone: international +39-091-6802962 • Fax: international +39-091-6883145 • E-mail: francesco.fabbian}@schering-pl.it

\textbf{References}


\textbf{AIDS-related non-Hodgkin’s lymphomas from an Italian area}

\textbf{ROBERTO FERRETTO, ROBERTO LUZZATI, DINO VENERI*, PIERANGELO ROVERE*, MAURIZIO SOLBIATI, ERCOLE CONCIA}

Institute of Immunology and Infectious Diseases; *Department of Hematology, University of Verona, Italy; **Section of Infectious Diseases, Hospital of Legnago (Verona), Italy

In a retrospective study, 42 (7.7%) of 545 patients with AIDS from a single area of Italy had non-Hodgkin’s lymphoma (28 systemic and 14 primary central nervous system lymphomas). The improved outcome and survival of treated patients outlines the clinical benefit of antineoplastic treatment in selected cases.

It has been widely recognized that patients with HIV-related immunosuppression are at increased risk of developing non-Hodgkin’s lymphomas (NHL) that include systemic, primary central nervous system (P-CNS-L) and body cavity-based lymphomas. At present in Italy the incidence of NHL is 3.5% according to the Centro Operativo AIDS. However, this figure represents only the first AIDS-defining condition, potentially missing lymphomas occurring at a later stage.

We have retrospectively evaluated the epidemiological and clinical characteristics of 42 cases (7.7%) of NHL among 545 patients with AIDS admitted to the Infectious Diseases Departments of the Verona area up to June 1997. Baseline characteristics of patients are shown in Table 1. Systemic-NHL were of B-cell type and classified as follows: 18 large cell, 4
Burkitt’s-type, 4 large cell immunoblastic, 2 low-grade B lymphomas. Three patients (11%) had exclusive nodal involvement and 25 one or more extranodal sites: 6 stomach, 4 each in liver, lung, bone marrow, 2 in the CNS, 1 each in testicle, spleen, gut, tongue, bladder and heart. Twenty patients (71%) presented with B symptoms. At diagnosis, 2 patients were in Ann Arbor stage I, 4 in stage II, 8 in stage III and 14 in stage IV. The diagnosis of P-CNS-L (B large cell lymphoma) was obtained by stereotactic brain biopsy in 12 cases and by post-mortem examination in 2 cases. The outcome and survival of treated patients are shown in Table 2. Chemotherapeutic and dose-intensity (range) regimens for patients with systemic-NHL were as follows: 6 patients CHOP (0.93-0.98), 2 ACVP (0.83-0.85), 3 ACVB (0.61-0.69), 2 VACOP-B (0.82-0.87), 1 ProMACE-MOPP (0.69). Seven patients received in addition intrathecal methotrexate (3-4 cycles). Five patients underwent radiation therapy (involved fields, total dose 30.5-40 Gy delivered over 3-4 weeks). All patients received trimethoprim/sulfamethoxazole prophylaxis and were not given anti-retroviral therapy up to completion of chemotherapy. A total of 7 patients had neutropenia and received G-CSF. The 8 patients (47%) who achieved complete remission did not have a previous AIDS diagnosis or a baseline CD4+ count < 100/mL. In contrast, 4 of the 9 remaining patients who showed partial remission or no response had a previous AIDS diagnosis and CD4+ count < 100/mL. The overall survival of 10 untreated patients (median 1 month, range 1-14) was significantly (p < 0.01) shorter than that of treated patients. Eleven patients with P-CNS-NHL underwent radiation therapy: 7 whole brain radiation (total dose 32-50 Gy delivered over 3-5 weeks) and 4 gamma-knife treatment (radiosurgical dose 46-70 Gy delivered to the tumor center in a single session).

AIDS-related NHL is quite frequent in our area and similar to that recently reported in USA by others. Our results confirm that the outcome and survival after therapy of systemic NHL substantially depend on both the underlying immune status and the stage of HIV disease. The prognosis of P-CNS-L is generally poor despite therapy since this tumor occurs in patients who are much more severely immunosuppressed. The surprisingly long survival of our patients treated with cerebral irradiation is due to exclusion from brain biopsy of patients with a life- expectancy of less than 6 months.

Key words
AIDS-related NHL

Correspondence
Roberto Ferretto, MD, Divisione Clinicizzata di Malattie Infettive, Ospedale Civile Maggiore, Borgo Trento, piazzale Stefani 1, 37126 Verona, Italy. Phone: international +39-045-8072384 • Fax: international +39-045-8340223.

References

Table 1. Baseline characteristics of patients.

<table>
<thead>
<tr>
<th></th>
<th>Systemic NHL</th>
<th>P-CNS-L</th>
</tr>
</thead>
<tbody>
<tr>
<td>(28 patients)</td>
<td>(14 patients)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>female</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Risk group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVDA</td>
<td>13</td>
<td>10</td>
</tr>
<tr>
<td>homosexuals</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>heterosexuals</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>transfusion recipients</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Median age, years (range)</td>
<td>32 (25-53)</td>
<td>31 (28-42)</td>
</tr>
<tr>
<td>Previous AIDS diagnosis</td>
<td>4 (15%)</td>
<td>9 (75%)</td>
</tr>
<tr>
<td>Median Karnofsky score</td>
<td>70 (60-90)</td>
<td>70 (60-80)</td>
</tr>
<tr>
<td>Median CD4 cell/µL (range)</td>
<td>122 (2-668)</td>
<td>32 (2-114)</td>
</tr>
</tbody>
</table>

NHL= non-Hodgkin’s lymphoma; P-CNS-L= primary central nervous system lymphoma; IVDA= intravenous drug abusers.

Table 2. Treatment, outcome and survival of patients.

<table>
<thead>
<tr>
<th># of pts.</th>
<th>Treatment</th>
<th>Outcome</th>
<th>Median surv.</th>
<th>months (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CT CT+RT</td>
<td>S</td>
<td>CR PR NR</td>
<td></td>
</tr>
<tr>
<td>NHL</td>
<td>17 10 3 2 2 8 4 5</td>
<td>11 (1-66)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-CNS-L</td>
<td>11 - - 11 3 6 2</td>
<td>9 (3-12)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NHL= non-Hodgkin’s lymphoma; P-CNS-L= primary central nervous system lymphoma; CR= complete remission (response); PR= partial remission (response); NR= no response; CT= chemotherapy; RT= radiotherapy; S= surgery.
Two-dimensional analysis of the structure of human von Willebrand factor

PAOLO PERUTELLI, SILVIA CATELLANI, PIER GIORGIO MORI

Hematology Laboratory, Hematology and Oncology Department, G.Gaslini Children’s Hospital, Genova, Italy

Human von Willebrand factor (vWF) is synthesized as an extra large polymer; then, it is converted to lower molecular weight plasma multimers, originally composed of intact 225-kDa subunits, by a metalloproteinase.1,2 Proteolysis generates two fragments of 140- and 176-kDa, which originate from cleavage of peptide bond Tyr842-Met843 and which represent vWF residues 1-842 and 843-2050, respectively; a very small amount of 189-kDa fragment can also be found in normal plasma.3 We describe here a two-dimensional (2-D) method to analyze plasma vWF structure.

Agarose gel electrophoresis was used as the first dimension to resolve the multimeric structure of vWF; the second dimension, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), allowed us to obtain information about proteolysis in vivo of this molecule. One-dimensional electrophoresis was performed on a vertical mini-gel apparatus (Mini-Protean II, Bio-Rad, Hercules, CA, USA). Plasma from normal subjects and type 2 von Willebrand disease (vWD) patients was diluted 1:5 in sample buffer; 30 µL were applied on 1.7% low gelling temperature agarose and run at 14 V for 20 h.4

vWF lanes were excised from the agarose gel, washed in distilled water for 30’ and soaked in reducing buffer (1% dithiothreitol and 1% SDS in stacking gel buffer, pH 6.8) for 30’ at room temperature under gentle agitation.

SDS-PAGE (5% polyacrylamide)5 was performed on mini-slab gel. The reduced lanes were applied on the top of the gel and electrophoresis was run at 200 V until the dye front reached the bottom of the gel.

Immunodetection was performed as described elsewhere;6 briefly, after electroblotting of 1-D gel, nitrocellulose membranes were incubated with rabbit antihuman vWF antiserum followed by incubation with alkaline phosphatase-labeled anti-rabbit antibody. BCIP/NBT was used as the chromogenic substrate.

Normal vWF shows a predominance of the intact 225-kDa subunit; the proteolytic fragments are present in low amounts (Figure 1). The 189-kDa fragment is poorly recognizable due to its low concentration in plasma. All subunits are resolved as broad bands having a whiter central area; the high glycosylation degree of vWF6 may be responsible for this pattern. Moreover, better detection of vWF subunits may be achieved using a pool of monoclonal antibodies rather than a polyclonal antibody.

Type 2A and 2B vWF lack the higher molecular weight multimers;7 2-D analysis shows that the lower molecular weight multimers are composed of higher amounts of proteolytic fragment than normal plasma (Figure 2).

The proposed method allows 2-D analysis of vWF; in this way, we could achieve information on multi-
merization and proteolysis of vWF. The method is simple, based on well-tested techniques such as agarose gel electrophoresis, SDS-PAGE, and immunoblotting; it is performed by mini-gel equipment, thus minimizing reagent consumption and analysis time. Moreover, vWF subunits are immunoenzymatically detected, without need of radiolabeled reagents.

Key words
von Willebrand factor, two-dimensional analysis

Correspondence
Paolo Perutelli, PhD, Hematology Laboratory, Hematology and Oncology Department, G. Gaslini Children’s Hospital, largo G. Gaslini, 5, 16147 Genoa, Italy. Phone: international +39-010-5636277 • Fax: international +39-010-3776590.

References
1. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44.

Long-term disease-free acute promyelocytic leukemia patients really can be cured at molecular level

GIOVANNI MARTINELLI, EMANUELA OTTAVANI, GIUSEPPE VISANI, NICOLETTA TESTONI, VITTORIO MONTEFUSCO, SANTE TURA

Institute of Hematology and Medical Oncology “Seràgnoli”; University of Bologna, Italy

The characteristic t(15;17) translocation involving chromosomes 15 and 17 is specifically associated with both the common and the variant subtypes of acute promyelocytic leukemia (APL) (M3 according to FAB classification). At the molecular level, it fuses genes encoding PML on chromosome 15 and the nuclear retinoic acid receptor-α (RARα) on chromosome 17. The subsequent expression of PML/RARα fusion mRNA provides a potential molecular marker that can be detected in leukemic cells taken from patients with APL. Using PML and RARα sequence specific primers, reverse transcription-polymerase chain reaction (RT-PCR) assays have been developed for detection of PML/RARα transcript in leukemic cells obtained from patients; these RT-PCR assays are more sensitive than conventional cytogenetic analysis.

We and others reported previously that the majority of the acute promyelocytic leukemia (APL) patients with long-lasting disease free survival were negative for PML/RARα transcript. We have now applied RT-PCR assay for PML/RARα analysis on bone marrow samples from 18 APL patients (8 female, 10 male; median age 31 years; range 14-59) with long-lasting complete remission (CR), after induction chemotherapy and consolidation (median 59 months; range 38-142 months from CR) in order to verify the validity of these observations further. All patients were in clinical and cytogenetic CR at the time of molecular evaluation. Nine of these patients had already been studied. In eleven patients karyotypic analysis on bone marrow aspirates was performed at diagnosis and confirmed the presence of the t(15;17) translocation. In the other 7 patients, using bone marrow samples frozen at the time of diagnosis we were able to detect the presence of the PML/RARα transcript by RT-PCR analysis.

Patients received different protocols of induction chemotherapy including an anthracycline (daunorubicin or idarubicin) alone or in combination with cytosine arabinoside (biological and clinical data are given in Table 1). After achievement of CR, one patient (PS in Table 1) was submitted to allogeneic bone marrow transplantation (BMT) from an HLA matched available donor. Fourteen patients were submitted to autologous BMT. Only two patients (GL and OD) were submitted to maintenance chemotherapy, and one patient (OM) withdrew from maintenance chemotherapy owing to hepatic toxicity. Remission bone marrow aspirates were obtained after achievement of CR and used for molecular analysis. Cytogenetic studies were performed as reported. RT-PCR analysis was performed as described elsewhere. Concerning the specificity and sensitivity of our RT-PCR method, we can detect one PML/RARα-positive cell diluted in 10⁻³-10⁻⁴ PML/RARα-negative cells.

The results of RT-PCR analysis in remission samples are schematically represented in Figure 1. Only the molecular results regarding the last sample for each patient are presented. In all cases but one, no PML/RARα transcripts were visible either on the ethidium bromide gels or after silver staining. At present, all but one of the patients are in continuous CR with a median follow up of 59 months (range 38-142). The patient who died (OM) had been persistently PCR positive at different times of analysis (+13, +15 and +32 months). After 39 months of CR, she presented a cytogenetic and a clinical relapse. A second CR was achieved after therapy with all-trans retinoic acid
Although she remained in CR for 5 months at a molecular level she was persistently positive. After a further relapse, she died from disease progression. Recently, \textit{in vitro} amplification of leukemia-specific fusion transcripts by RT-PCR has been applied to the detection of minimal residual leukemia (MRL).\textsuperscript{5} The persistence of the PML/RAR\textsubscript{H9251} transcript in early post-remission APL samples has been associated with early clinical relapse within a few months.\textsuperscript{1,6} Several recent studies indicate that molecular monitoring of the PML/RAR\textsubscript{H9251} fusion transcript in APL could allow identification of patients who need further antileukemic therapy.\textsuperscript{7} On the other hand, we and others\textsuperscript{8} have reported that long term survival of APL is associated with eradication of cells carrying the specific PML/RAR\textsubscript{x} rearrangement, indicating that PCR negativity should be considered the therapeutic goal in these patients.

Regarding the role of consolidation and maintenance chemotherapy,\textsuperscript{9} most of our APL patients received, as a consolidation of the cytotoxic chemotherapy induction of APL, an allogeneic (1 patient) or autologous bone marrow re-infusion after chemotherapy ablation (14 patients). The only patient in our series who had a clinical relapse did not receive any consolidation therapy because of intercurrent infections. These observations suggest that the cure of APL by transplantation is accompanied by elimination, at least below our RT-PC sensitivity levels, of

\begin{table}
\centering
\caption{Clinical and therapeutic characteristics of the APL patients.}
\begin{tabular}{lllllllllll}
\hline
UPN & Pt. & Age (yrs) & Sex & Breakpoint & Year of diagnosis & Induction & Consolidation & Maintenance & BMT & 1st CR & Survival Status \\
\hline
1 & B.V. & 43 & M & BCR3 & 1993 & ATRA & Dauno+ARAC & No & Auto & 46 & 47 CR \\
2 & A.M. & 37 & M & BCR1 & 1993 & ATRA+Dauno & ATRA & DAE & Auto & 52 & 54 CR \\
7 & P.E. & 31 & M & BCR1 & 1986 & Dauno+ARAC & AMSA+ARAC & No & Auto & 141 & 142 CR \\
9 & C.F. & 51 & M & BCR1 & 1993 & ATRA & IDA+ARAC & No & Auto & 44 & 46 CR \\
10 & R.A. & 31 & F & & 1987 & Dauno & AMSA+MitelGAG & AMSA+ARAC & No & Auto & 7 & 131 CR after 2\textsuperscript{nd} relapse \\
11 & M.C. & 37 & M & BCR1 & 1992 & IDA+ARAC & IDA+ARAC & Mitox+VP16 & IDA+6TG+ARAC & No & Auto & 18 & 65 CR after 2\textsuperscript{nd} relapse \\
12 & O.D. & 17 & M & BCR1 & 1991 & IDA+ARAC & IDA+ARAC & Novan+ARAC & IDA+ARAC & No & Auto & 18 & 65 CR after 2\textsuperscript{nd} relapse \\
13 & S.G. & 20 & M & BCR3 & 1991 & IDA & IDA+ARAC & Novan+6TG & No & 75 & 77 CR \\
15 & S.D. & 14 & F & BCR3 & 1993 & ATRA+Dauno & Dauno+ARAC & No & Auto & 42 & 43 CR \\
16 & S.A. & 28 & M & BCR3 & 1993 & ATRA+IDA & IDA+ARAC & No & Auto & 51 & 52 CR \\
18 & O.M. & 50 & F & BCR1 & 1991 & IDA & ARAC+IDA & Mitox+VP16 & No & No & 37 & 53 Died from APL relapse \\
\hline
\end{tabular}
\end{table}

(ATARa). Although she remained in CR for 5 months at a molecular level she was persistently positive. After a further relapse, she died from disease progression.

Regarding the role of consolidation and maintenance chemotherapy,\textsuperscript{9} most of our APL patients received, as a consolidation of the cytotoxic chemotherapy induction of APL, an allogeneic (1 patient) or autologous bone marrow re-infusion after chemotherapy ablation (14 patients). The only patient in our series who had a clinical relapse did not receive any consolidation therapy because of intercurrent infections. These observations suggest that the cure of APL by transplantation is accompanied by elimination, at least below our RT-PC sensitivity levels, of
residual cells expressing the PML/RARα transcript. However, the prognostic significance of a positive RT-PCR post-induction treatment in APL is better defined5,6,10 than in CML, and it is clear that persistence of the PML/RARα transcript is fatally associated with clinical relapse (as in our patient OM). This means that the RT-PCR assay is a useful prognostic tool not only in the induction and consolidation treatment phases, but also after transplantation and during long-lasting follow-up.

Contributions and Acknowledgments
We wish to thank Dr. Francesco Lo Coco and Daniela Diverio for supporting our study. We are grateful to Mr. Robin M.T. Cooke for checking the English version of the manuscript.

Funding
This work was supported by the Italian Research Cancer Association (A.I.R.C.) and by C.N.R. Detection of minimal residual disease target project “ACRO” no. 93.02257. PF39, no. 952206, and MURST 40%-60%.

Correspondence
Giovanni Martinelli, M.D., Institute of Hematology and Medical Oncology "Seràgnoli", Policlinico S. Orsola, Via Massarenti 9, 40138, Bologna, Italy. Phone: international +39-051-6363680 • Fax: international +39-051-398973.

Manuscript processing
Manuscript received March 9, 1998; accepted June 18, 1998.

References
Granulocyte colony-stimulating factor administered as a single intraperitoneal injection modifies the lethal dose of irradiated B6D2F1 mice

Anna Sureda,* Elisabeth Kádár,* Agustí Valls,* Joan García-López*

*Departament de Criobiologia i Teràpia Cellular, Institut de Recerca Oncològica, Hospital Duran i Reynals, Barcelona, Spain; °Servei de Radioteràpia, Hospital de l’Esperança, Barcelona, Spain

Granulocyte colony stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates the proliferation of progenitor myeloid cells. We have previously demonstrated that recombinant human G-CSF (rhG-CSF) significantly improves survival of lethally irradiated B6D2F1 mice when administered as a single intraperitoneal dose of 1 mg/kg 2 hours after a lethal dose (LD95/30) irradiation. In our model, rhG-CSF is also able to modify the LD95/30 in irradiated animals and 1.1 has been found to be the dose modification factor (the ratio of LD95/30 for mice treated with rhG-CSF to that for control animals).

Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates the in vitro proliferation of progenitor cells committed to the myeloid lineage. In animal models, G-CSF is able to stimulate granulocyte recovery and to promote survival after lethal irradiation when administered as daily injections, indicating a possible influence on more primitive progenitors. In these cases, G-CSF modifies both the lethal dose (LD95/30 and 50/30) (LD95/30 and 50/30) providing evidence that G-CSF protects animals from the lethal effects of irradiation. We have previously demonstrated that recombinant human G-CSF (rhG-CSF) administered as a single intraperitoneal dose of 1 mg/kg 2 hours after a LD95/30 irradiation significantly improves survival of lethally irradiated B6D2F1 mice (78% vs 7%, p<0.001). Herein, we want to report the effect of rhG-CSF on survival after different doses of total body irradiation (TBI) and the LD95/30 variation in our model.

Eight week B6D2F1 female mice were maintained in a sterile unit with filtered air on hardwood chip contact bedding (Panlab, SL) from irradiation to day +30 and provided with commercial sterile rodent chow and sterile water supplemented with neomycin sulfate (Gibco Lab, 40 mg/L) and cotrimoxazol (Soltrim®, Almirall Lab, 1.6 g/L). A 60Co source (Aeldon II, Compagnie General de Radiologie, General Electric) was used to deliver total-body 60Co gamma irradiation (1.25 MeV). Mice were initially irradiated up to a total dose of 1000 cGy at a dose rate of 50 cGy/min, previously established as the LD95/30. Irradiation was progressively increased to a total dose of 1100 cGy at the same dose rate in order to find the LD95/30 for rhG-CSF-treated animals and subsequently decreased to 925 cGy. rhG-CSF (provided by Amgen, Thousand Oaks, CA, USA) was administered as a single dose of 1 mg/kg (20 µg) and diluted in saline to a final volume of 250 µL, 2 hours after the irradiation. Control mice were injected with 250 mL of physiological saline. A minimum of 30 animals from both groups was used to analyze overall survival for each one of the total doses analyzed. Surviving animals were recorded daily for 30 days. Differences in survival of irradiated rhG-CSF-treated and controls were determined using the Mantel-Peto-Cox test.

Results are shown in Figures 1 and 2. Survival post-TBI significantly increases in the control group when reducing the total dose (40% at 925 cGy vs 7% at 1000 cGy, p<0.001) (Figure 1). Nevertheless, differences in survival between both groups of animals are still significant at the 925 cGys point (40% vs 95%, p<0.005).

In the rhG-CSF group, there is a progressive decrease in survival after TBI when total dose pro-
gressively increases up to 1100 cGy (Figure 2); there are significant differences between survivals of rhG-CSF-treated and control animals at total doses of 1025 (60% vs 7%, p<0.001) and 1050 cGy (27% vs 0%, p<0.025). However, no significant differences can be observed at 1100 cGy (5% vs 0%, NS), as has been previously reported in a murine model with daily injections of G-CSF.5 A dose of 1100 cGy can thus be considered the LD95/30 in our model. Consequently, 1.1 has been found to be the dose modification factor (the ratio of LD95/30 for mice treated with rhG-CSF to that for control animals).

In our model, rhG-CSF administered as a single intraperitoneal dose is also able to modify the LD95/30 in irradiated animals, as demonstrated by others when rhG-CSF is administered in daily doses.4-6 Nevertheless, rhG-CSF was not effective in enhancing survival when total dose was higher than 1050 cGy, suggesting that the radioprotective effect of G-CSF requires a certain number of residual surviving stem cells.

**Key words**
Granulocyte colony-stimulating factor, total body irradiation, hematopoietic injury

**Funding**
This work was partially supported by grant number 93/0381 from the FIS.

**Correspondence**
Anna Sureda, M.D., Departament de Criobiologia i Teràpia Cellular, Institut de Recerca Oncològica, Hospital Duran i Reynals, Autovia de Castelldefels, Km 2.7, 08907 Barcelona, Spain. Phone: international +34-93-2633817 • Fax: international +34-93-2607776.

**References**

**Figure 2.** Effect of a single intraperitoneal injection of rhG-CSF (1 mg/kg, 2 hours after irradiation) on survival of irradiated mice with a total dose of 925 cGy, 950 cGy, 975 cGy, 1000 cGy, 1025 cGy, 1050 cGy and 1100 cGy.